Estimation of Retinol Binding Protein as A Near Biomarker of Diabetic Nephropathy in type 2 Diabetic Mellitus Patients at Al-Najaf Province

Abstract

Introduction: Diabetic nephropathy is among the most important microvascular consequences of diabetes (DN). It is marked by a higher excretion rate of urine albumin, a blood pressure rising, and a deterioration in renal function, all of which contribute to end-stage renal disease. Insulin resistance and obesity have been linked to retinol binding protein (RBP), a newly identified adipocytokine. Peripheral tissues, such as the liver and adipose tissues, produce retinol binding protein.  Aim of study: The aim of this study was to investigate the potential utility of retinol binding protein (RBP) as a biomarker for type 2 diabetic nephropathy detection. Methodology: Patients with long-term T2DM and healthy control subjects were recruited for this case control research.50 patients (26 males and 24 female) selected from renal and diabetic centers in AL-Saader medical city in the period from March 2022 to May 2022. Results: The findings of these studies indicated a significant increase in biochemical parameters in DN patient other than healthy control.  Conclusion: This research found that the following in persons with type 2 diabetes, RBP levels can be utilized as a biomarker for the early diagnosis of diabetic nephropathy. Further studies should be conducted to cover a larger number of patients and to approve the findings.